Mesoblast Ltd. appointed Josh Muntner to the position of CFO.
Muntner, who will be based in New York, replaces outgoing CFO Paul Hodgkinson.
Previously, Muntner led corporate development and financial transactions at biotechnology company ContraFect Corp.
Ignite Partners advised the company on Muntner's appointment.
Australia-based Mesoblast develops cell-based medicines.
